Introduction
The variety of available HIV prevention interventions for persons who inject drugs (PWID)which includes needle and syringe exchange programs, opioid substitution treatment (OST), antiretroviral treatment (ART), and most recently, pre-exposure prophylaxispose a challenge to the scientific community to develop the knowledge base needed to determine optimal combinations of these prevention interventions for specific populations of PWID. In addition, research and surveillance methodologies that enable monitoring and adjusting combined prevention packages to rapidly respond to epidemiological exigencies are urgently needed.
High-seroprevalent HIV epidemics among PWIDwith seroprevalence reaching 40% or higherhave occurred in many different areas throughout the world, including high-income countries, transitional countries, and middle/low-income countries (Mathers et al., 2008) . The implementation of combined HIV prevention interventions, particularly needle and syringe exchange programs (NSEPs), OST, and anti-retroviral treatment (ART) for HIV infection, has helped to control the HIV epidemic among PWID in a number of high-income areaswith HIV incidence among PWID reduced to <1/100 person-years at risk, including Amsterdam (de Vos, van der Helm, Matser, Prins, & Kretzschmar, 2013) , New York City (Des Jarlais et al., 2010) , and Vancouver, Canada (Montaner et al., 2012) .
Injecting drug use is driving HIV epidemics in many countries in Eastern Europe, Central Asia, and Southeast Asia (European Center for Disease Control [ECDC], 2009) . Whether combined prevention programming will bring these high seroprevalence epidemics under control in resource-limited settings (transitional and low-and middle-income countries) is a critical question in HIV prevention.
There are several aspects of HIV epidemics among PWIDs in transitional, low-, and middle-income countries that make implementation of combined HIV prevention programs particularly challenging, including limited resources, marked stigmatization of PWID, and discrimination due to PWID belonging to ethnic minority groups (Des Jarlais, Pinkerton, et al., 2013) . Further, in many countries, injecting drug use is viewed as a "foreign," "Western" practice that undermines the traditional values of the society. In some countries, programs such as syringe exchange and OST are viewed as perpetuating drug use. In such situations, national leaders may oppose evidence-based HIV prevention programs. The Russian opposition to methadone maintenance therapy is an example of this (Elovich & Drucker, 2008) .
This report provides preliminary evidence of the potential effectiveness of combined HIV prevention on the very high seroprevalence epidemic among PWID in Tallinn, Estonia, a transitional country. First we describe the history of the HIV epidemic among PWID in Tallinn. We then review the implementation history of interventions to reduce HIV transmission among PWID in Tallinn, as well as epidemiological particulars, obtained from community-based cross-sectional surveys of PWID in 2005 PWID in , 2007 PWID in , 2009 PWID in , and 2011 . Based on these data, we then apply a mathematical model of injectionassociated HIV transmission to estimate the impact of combined prevention on the HIV epidemic among PWID in Tallinn.
Background
Estonia is a small country in northeastern Europe with a population of 1,340,000 (Statistics Estonia, 2012) . A very rapid HIV epidemic began in Estonia in the late 1990s and reached peak incidence in 2001 (108 infections per 100,000 person-years; ECDC, 2009). Though lessened, the epidemic continues. In 2011, Estonia had the third highest per capita HIV incidence in Europe (27.3/100,000; ECDC, 2012). According to a global review of injecting drug use and HIV epidemiology, Estonia has one of the highest concentrations of injecting drug users among people aged 15-64 years (1.5% in 2007), which is coupled with a very high HIV prevalence among PWIDs (Mathers et al., 2008) . Studies conducted among PWIDs in Estonia have found very high HIV prevalence rates (40-90%; Abel-Ollo et al., 2009; Platt et al., 2006; Uusküla et al., 2008; Wilson, Sharma, Zilmer, Kalikova, & Uusküla, 2007) . In Tallinn, Estonia's capital and largest city, approximately 50% of the city's 5000-7000 PWIDs are already infected with HIV (Uusküla, Rajaleid, Talu, Abel-Ollo, & Des Jarlais, 2013) .
Estonia's capacity to manage its response to HIV and AIDS has increased greatly over the past decade, particularly through funding from the Global Fund to Fight HIV/ AIDS, Tuberculosis, and Malaria (The Global Fund to Fight AIDS, Tuberculosis and Malaria, 2007) . Global Fund support was also instrumental in building capacity for the governmental and nongovernmental sectors to interact constructively with each other. These cooperative actions included establishing systems for channeling funds through the government to nongovernmental organizations and mechanisms for cooperation (Drew et al., 2008) . These collaborative efforts resulted in several initiatives, including efforts to reduce the risk of harm faced by PWIDs by scaling up syringe exchange programs and drug treatment programs. ART is available free of charge to all HIV-infected persons in need, including those without health insurance. There has been a significant increase in the number of persons on ART over the past years: from 250 (Rüütel, Trummal, Salekesin, & Pervilhac, 2011) in 2005 to 2156 (Estonian Ministry of Social Affairs, 2012; Uusküla et al., 2011) in 2011.
In Estonia, HIV prevention services are provided by nonprofit organizations, mainly funded by the state according to the operational plan of the national HIV/ AIDS strategy . Table 1 presents information on the major HIV prevention services provided for PWID in Tallinn. These services are described further below.
Needle and syringe exchange programs NSEPs were initiated in 1997 in Estonia. In 2009, there were nine organizations providing syringe exchange and HIV and drug counseling services (three in Tallinn). PWIDs may obtain sterile syringes either directly at an exchange site or from syringe exchange community outreach workers. In order to protect confidentiality, exchanges do not record information of the persons obtaining sterile needles and syringes. Based on the numbers of syringes distributed and the estimated numbers of PWID in Tallinn (∼6000 at the end of 2000s), we estimate that about 120 syringes per PWID per year have been distributed in Tallinn since 2008.
Free condom distribution
Syringe exchange programs also provide free condoms at fixed site locations and through community outreach workers. As with syringes, information is not collected by the program about persons obtaining free condoms. 
Modeling the effectiveness of combined prevention programs
We estimated the effectiveness of combined HIV prevention for PWID in Estonia using a mathematical model of injection-associated HIV acquisition based on Edward Kaplan's "needles that kill" modeling framework (Kaplan, 1989 ). In our model, the incidence of new HIV infections among PWID is a direct function of the number of injections with borrowed syringes and the proportion of borrowed syringes that are contaminated with HIV:
Incident infection rate ¼ bct where b is the average number of injections with borrowed syringes per PWID per year; c is the proportion of borrowed syringes that are contaminated with HIV; and t denotes the per-injection probability of HIV transmission from a contaminated syringe to a previously uninfected PWID (further explication of the model is provided in Pinkerton, 2010) . The proportion of contaminated syringes, c, depends upon the rate at which used syringes are exchanged for sterile onesthe greater the exchange rate, the shorter the average time each syringe spends in circulation, hence the less likely it is to become contaminated with HIV before (potentially) being used by another person. Specifically:
where p is the prevalence of existing infection among PWID; x denotes the number of syringes exchanged per PWID per year; and s represents the percent of PWID on ART who have suppressed viral load. Persons with suppressed viral load were assumed incapable of effectively contaminating a syringe with HIV. Both the new infection rate and the contamination rate are measured in years, so that the model estimates the rate of incident cases of HIV per 100/person-years.
Results
Cross-sectional RDS studies recruiting PWID were conducted in Tallinn in 2005 (n = 350), in 2007 (n = 350), in 2009 (n = 329), and in 2011 (n = 350). Table 2 presents data on HIV prevalence, HIV testing, and ART coverage among study participants during these years. Table 2 indicates that the proportion of HIV-seropositive PWID in Tallinn receiving ART has increased greatly over the period of the four RDS surveys, reaching 40% among HIV-seropositive persons in 2011.
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Combined prevention participation among current injecting drug users In 2011, 350 PWIDs (174 of whom were living with HIV) were surveyed. One-third (18.5%) of study participants were on OST, two-thirds (68.9%) were current users of NSEP, 40% of HIV-infected respondents were on ART, and over half (55.7%) of HIV-uninfected PWID reported being tested for HIV within the 12 months prior to study participation. (OST included both short-term detoxification programs and long-term maintenance programs in these analyses.) Coverage with selected preventive interventions (ART, NSEP, VCT, and OST) was assessed separately for HIV-infected and uninfected PWIDs. Only 12.1% of HIV-positive study respondents did not participate in any of the three applicable interventions (ART, NSEP, OST): 42.5% reported utilizing a single intervention, 30.5% participated in two interventions, and 11.5% in all three interventions. Most HIV-negative PWID (77.3%) utilized one or more of the applicable interventions (VCT, OST, and NSEP): 34.7% reported utilizing a single intervention, 36.4% participated in two interventions, and 5.7% participated in all three interventions. Other than ART, intervention utilization was not significantly different between HIV-positive and at-risk persons (Figure 1) .
Modeling the combined effectiveness of syringe exchange and ART
Tallinn's syringe exchange programs have grown rapidly in recent years, from 38 syringes exchanged per PWID in 2005 to 125 syringes in 2011. During this same period, the proportion of PWID receiving ART grew from 0% to 40%.
The results of the modeling analysis of the impact of syringe exchange and ART on the incidence of HIV infection among PWID in Tallinn are presented in Table 3 . The modeled incidence decreased rapidlyfrom 20.7/100 person-years in 2005 to 7.5/100 person-years in 2011as ART uptake and the number of syringes exchanged by Tallinn's NSEPs increased over this period.
Because the number of methadone maintenance treatment (approximately 300) is extremely small compared to the estimated numbers of PWID in Tallinn (∼6000), we did not include methadone treatment as a prevention strategy in the combined prevention model. A straightforward method for incorporating methadone maintenance treatment into the incidence estimation model would be to assume that persons in methadone treatment cease injecting drugs. (Note that this is an optimistic assumption, in that many persons in methadone treatment continue to inject.) This would reduce the size of the drug-injecting population by the number of persons in methadone maintenance treatment. Reducing the population of PWID by 300 (a 5% reduction versus the estimated 6000 PWID in Tallinn) would not have a noticeable effect on the HIV incidence rate among PWID, which also would be reduced by approximately 5%.
Discussion
Research in high-income countries has documented that large-scale implementation of needle syringe programs may have an impact within a short time period (2-3 years; Des Jarlais, Feelemyer, Modi, Abdul-Quader, & Hagan, 2013) , but achieving the maximal impact at the population level may take 5-15 years after implementation of combined prevention (Des Jarlais, Arasteh, & Friedman, 2011; Des Jarlais et al., 2005) .
We conducted a series of community-based crosssectional surveys of PWID in Tallinn in 2005, 2007, 2009, and 2011 , and used a mathematical model to estimate the potential impact on HIV incidence of NSEP and ART on this high HIV prevalence epidemic. The modeled incidence was high at the beginning of the observation period (20.7/100 person-years in 2005) but decreased rapidly within 5 years to 7.5/100 person-years in 2011. These estimates indicating a decrease in HIV incidence during the study time period are in the same direction as the Estonian surveillance data (the number of newly reported HIV cases from all transmission routes in Tallinn decreased from 263 in 2005 to 205 in 2011 Estonian Health Board, 2012) .
Our incidence estimates suggest that, in combination, high but achievable NSEP syringe distribution rates (∼120 syringes per year per PWID) and moderate levels of ART coverage (20-40%) can have a marked effect on HIV incidence among PWID. Additional expansion of NSEPs, increasing ART coverage among HIV-infected PWID, and increasing the proportion of persons on ART who achieve viral suppression would further enhance the impact of these interventions.
The set of interventions implemented in Tallinn as part of the combined prevention package was site and epidemic specific. Although scaling up ART (including for PWID) was possible in Estonia, it might not be so in other locations. Estonia has been unable to provide long-term maintenance OST at the public health scalehowever, OST has been a vital prevention component in several other countries (Gowing, Farrell, Bornemann, Sullivan, & Ali, 2011; MacArthur et al., 2012) . Further, interventions that reduce the infectiousness of HIVpositive persons need to be combined with strategies that reduce HIV susceptibility in the uninfected.
Our study has several limitations. The cross-sectional survey data were obtained from a non-probability sample of PWID, which may have implications for the representativeness of the study results. However, the sampling technique used in this study (RDS) is known to mitigate some of the limitations of convenience sampling (Malekinejad et al., 2008) . It is unlikely that the marked increase we observed in the proportion of HIV+ PWID on ART is due to sampling bias only.
PWIDs in Tallinn can also obtain sterile injection equipment from pharmacies (Vorobjov et al., 2009) . We were unable to determine the numbers of syringes obtained from pharmacies in the 2005-2009 time period. Despite some imprecision in determining the numbers of sterile needles and syringes obtained by PWIDs in Tallinn over the time period covered by the surveys, it is clear from the data in Table 1 that there was a very substantial increase in the provision of sterile-injecting equipment.
Our modeling included injecting-related HIV transmission but not sexual transmission, so that the actual HIV incidence among PWID in Tallinn is likely to be somewhat higher than our estimates suggest. As most of the sexual transmission is likely to be from PWID to non-injecting sexual partners (Uusküla, McMahon, et al., 2013) , sexual transmission to PWID is not likely to be substantial.
Despite these limitations, our findings strongly suggest that, in Tallinn, the combination of NSEP, HIV testing, and scaling up ART for those in need has helped to reduce the magnitude of the HIV epidemic and may be vital for keeping the epidemic under control. Combined prevention targeting both acquisition-and transmissionrelated risks among those affected by HIV is important. The set of combined interventions should be site and epidemic specific, provided at a public health scale, and responsive to community and governmental stakeholders. (Pinkerton, 2011 ) and a 0.0066 perinjection probability of HIV transmission (Kaplan & O'Keefe, 1993) .
